Literature DB >> 26677941

Age-related upper limits of normal for maximum upright exercise pulmonary haemodynamics.

Rudolf K F Oliveira1, Manyoo Agarwal2, Julie A Tracy3, Abbey L Karin3, Alexander R Opotowsky4, Aaron B Waxman3, David M Systrom5.   

Abstract

The exercise definition of pulmonary hypertension was eliminated from the pulmonary hypertension guidelines in part due to uncertainty of the upper limits of normal (ULNs) for exercise haemodynamics in subjects >50 years old.The present study, therefore, evaluated the pulmonary haemodynamic responses to maximum upright incremental cycling exercise in consecutive subjects who underwent an invasive cardiopulmonary exercise testing for unexplained exertional intolerance, deemed normal based on preserved exercise capacity and normal resting supine haemodynamics. Subjects aged >50 years old (n=41) were compared with subjects ≤50 years old (n=25). ULNs were calculated as mean + 2 sdPeak exercise mean pulmonary arterial pressure was not different for subjects >50 and ≤50 years old (23 ± 5 versus 22 ± 4 mmHg, p=0.22), with ULN of 33 and 30 mmHg, respectively. Peak cardiac output was lower in older subjects (median (interquartile range): 12.1 (9.4-14.2)versus16.2 (13.8-19.2) L·min(-1), p<0.001). Peak pulmonary vascular resistance was higher in older subjects compared with younger subjects (mean ± sd: 1.20 ± 0.45 versus 0.82 ± 0.26 Wood units, p<0.001), with ULN of 2.10 and 1.34 Wood units, respectively.We observed that subjects >50 and ≤ 50 years old have different pulmonary vascular responses to exercise. Older subjects have higher pulmonary vascular resistance at peak exercise, resulting in different exercise haemodynamics ULNs compared with the younger population.
Copyright ©ERS 2016.

Entities:  

Mesh:

Year:  2015        PMID: 26677941     DOI: 10.1183/13993003.01307-2015

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  25 in total

Review 1.  Translational Advances in the Field of Pulmonary Hypertension. Focusing on Developmental Origins and Disease Inception for the Prevention of Pulmonary Hypertension.

Authors:  Bradley A Maron; Steven H Abman
Journal:  Am J Respir Crit Care Med       Date:  2017-02-01       Impact factor: 21.405

Review 2.  Update in Pulmonary Vascular Disease 2015.

Authors:  Bradley A Maron; Mark T Gladwin; Marc A Simon
Journal:  Am J Respir Crit Care Med       Date:  2016-06-15       Impact factor: 21.405

3.  Update in Pulmonary Vascular Disease 2016 and 2017.

Authors:  Evan L Brittain; Thennapan Thennapan; Bradley A Maron; Stephen Y Chan; Eric D Austin; Edda Spiekerkoetter; Harm J Bogaard; Christophe Guignabert; Roxane Paulin; Roberto F Machado; Paul B Yu
Journal:  Am J Respir Crit Care Med       Date:  2018-07-01       Impact factor: 21.405

4.  Network Analysis to Risk Stratify Patients With Exercise Intolerance.

Authors:  William M Oldham; Rudolf K F Oliveira; Rui-Sheng Wang; Alexander R Opotowsky; David M Rubins; Jon Hainer; Bradley M Wertheim; George A Alba; Gaurav Choudhary; Adrienn Tornyos; Calum A MacRae; Joseph Loscalzo; Jane A Leopold; Aaron B Waxman; Horst Olschewski; Gabor Kovacs; David M Systrom; Bradley A Maron
Journal:  Circ Res       Date:  2018-02-05       Impact factor: 17.367

5.  Pulmonary hemodynamics responses to hypoxia and/or CO2 inhalation during moderate exercise in humans.

Authors:  Stéphane Doutreleau; Irina Enache; Cristina Pistea; Bernard Geny; Anne Charloux
Journal:  Pflugers Arch       Date:  2018-03-03       Impact factor: 3.657

6.  Pulmonary Vascular and Right Ventricular Burden During Exercise in Interstitial Lung Disease.

Authors:  Rudolf K F Oliveira; Aaron B Waxman; Paul J Hoover; Paul F Dellaripa; David M Systrom
Journal:  Chest       Date:  2020-03-12       Impact factor: 9.410

Review 7.  Pulmonary Vascular Disease: Hemodynamic Assessment and Treatment Selection-Focus on Group II Pulmonary Hypertension.

Authors:  Bhavadharini Ramu; Brian A Houston; Ryan J Tedford
Journal:  Curr Heart Fail Rep       Date:  2018-04

8.  Arterial vascular volume changes with haemodynamics in schistosomiasis-associated pulmonary arterial hypertension.

Authors:  Farbod N Rahaghi; Joan F Hilton; Ricardo A Corrêa; Camila Loureiro; Jaquelina S Ota-Arakaki; Carlos G Y Verrastro; Michael H Lee; Claudia Mickael; Pietro Nardelli; David A Systrom; Aaron B Waxman; George R Washko; Raúl San José Estépar; Brian B Graham; Rudolf K F Oliveira
Journal:  Eur Respir J       Date:  2021-05-06       Impact factor: 16.671

9.  Insights From Invasive Cardiopulmonary Exercise Testing of Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

Authors:  Phillip Joseph; Carlo Arevalo; Rudolf K F Oliveira; Mariana Faria-Urbina; Donna Felsenstein; Anne Louise Oaklander; David M Systrom
Journal:  Chest       Date:  2021-02-10       Impact factor: 10.262

10.  Open label study of ambrisentan in patients with exercise pulmonary hypertension.

Authors:  Sergio A Segrera; Laurie Lawler; Alexander R Opotowsky; David Systrom; Aaron B Waxman
Journal:  Pulm Circ       Date:  2017-05-12       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.